Genetically modified tumor cell vaccines

Surgical Oncology Clinics of North America

Volumn 7, Issue 3, 1998, Pages 471-485

  Hodi, F S ^a   Dranoff, G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CANCER GENETICS; CANCER RESEARCH; GENE TECHNOLOGY; GENE TRANSFER; HUMAN; IMMUNIZATION; MALIGNANT NEOPLASTIC DISEASE; REVIEW; VACCINATION;

EID: 0031904265     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30256-4     Document Type: Review

References (76)

1. Abdel-Wahab Z. Weltz C. Hester D. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells Cancer 80 1997 401 412
2. Addison C. Bracials T. Ralston R. Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model Proc Natl Acad Sci U S A 92 1995 8522 8526
3. Allione A. Consalvo M. Nanni P. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants Cancer Res 54 1994 6022 6026
4. Antin J.H. Graft-versus-leukemia: No longer an epiphenomenon Blood 82 1993 2273 2277
5. Barth A. Hoon D.S.B. Foshag L.J. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response Cancer Res 54 1994 3342 3345
6. Belli F. Arienti F. Sule-Suso J. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability Cancer Immunol Immunother 44 1997 197 203
7. Berd D. Murphy G. Maguire H.C. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases Cancer Res 51 1991 2731 2734
8. Berkner K.L. Development of adenovirus vectors for the expression of heterologous genes Biotechniques 6 1988 616 629
9. Bett A. Haddara W. Preveo L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3 Proc Natl Acad Sci U S A 91 1994 8802 8806
10. Boczkowski D. Nair S.K. Snyder D. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo J Exp Med 184 1996 465 472
11. Boon T. van der Bruggen P. Human tumor antigens recognized by T lymphocytes J Exp Med 183 1996 725 729
12. Boon T. Cerottin J-C. Van den Eynde B. Tumor antigens recognized by T lymphocytes Annu Rev Immunol 12 1994 337 365
13. Brunda M.J. Luistro L. Warrien R.R. Antitumor and antimetastatic activity of interleukin-12 against murine tumors J Exp Med 178 1993 1223 1230
14. Bueler H. Mulligan R. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: Enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1 Mol Med 2 1996 545 555
15. Bystryn J. Oratz R. Harris M. Immunogenicity of a polyvalent melanoma antigen vaccine in humans Cancer 61 1988 1065 1070
16. Carey T. Lloyd K. Takahashi T. AU cell-surface antigen of human malignant melanoma: Solubilization and partial characterization Proc Natl Acad Sci USA 76 1979 2898 2902
17. Caux C. Dezutter-Dambuyant C. Schmitt D. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells Nature 360 1992 258 261
18. Chen L. McGowan P. Ashe S. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity J Exp Med 179 1994 523 532
19. Chen S-H. Kosai K-I. Xu B. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained anti-tumor immunity prolongs animal survival Cancer Res 56 1996 3758 3762
20. Conry R.M. Wider G. Lobuglio A.F. Selected strategies to augment polynucleotide immunization Gene Therapy 3 1996 67 74
21. Consalvo M. Mullen C. Modesti A. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory J Immunol 154 1995 5302 5312
22. Cox A. Skipper J. Chen Y. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines Science 264 1994 716 719
23. Culver K.W. Ram Z. Wallbridge S. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors Science 256 1992 1550 1552
24. Danos O. Mulligan R.C. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges Proc Natl Acad Sci U S A 85 1988 6460 6464
25. Disis M.L. Bernhard H. Shiota F.M. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines Blood 88 1996 202 210
26. Dranoff G. Mulligan R.C. Gene transfer as cancer therapy Adv Immunol 58 1995 417 454
27. Dranoff G. Jaffee E. Lazenby A. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U S A 90 1993 3539 3543
28. Ellem K.A.O. O’Rourke M.G.E. Johnson G.R. A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy Cancer Immunol Immunother 44 1997 10 20
29. Engelhardt J. Ye X. Doranz B. Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver Proc Natl Acad Sci U S A 91 1994 6196 6200
30. Fass D. Davey R.A. Hamson C.A. Structure of a murine leukemia virus receptorbinding glycoprotein at 2.0 A resolution Science 277 1997 1662 1666
31. Fearon E.R. Pardoll D.M. Itaya T. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response Cell 60 1990 397 403
32. Forni G. Fujiwara H. Martino F. Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy Cancer Metastasis Rev 7 1988 289 309
33. Gansbacher B. Zier K. Daniels B. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity J Exp Med 172 1990 1217 1224
34. Goydos J. Elder E. Whiteside T. A Phase I trial of a synthetic mucin peptide vaccine: Induction of specific immune reactivity in patients with adenocarcinoma J Surg Res 63 1996 298 304
35. Guinan E. Gribben J. Boussiotis V. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity Blood 84 1994 3261 3282
36. Hardy S. Kitamura M. Harris-Stansil T. Construction of adeonvirus vectors through cre-lox recombination J Virol 71 1997 1842 1849
37. Houghton A. Cancer antigens: Immune recognition of self and altered self J Exp Med 180 1994 1 4
38. Hsu F. Benike C. Fagnoni F. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nature Medicine 2 1996 52 58
39. Hui K.M. Ang P.T. Huang L. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes Gene Therapy 4 1997 783 790
40. Jager E. Bernhard H. Romero P. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma associated antigens Int J Cancer 66 1996 162 169
41. Jager E. Ringhoffer M. Dienes H.P. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo Int J Cancer 67 1996 54 62
42. Jager E. Ringhoffer M. Karbach J. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8 + cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo Int J Cancer 66 1996 470 476
43. Khazaie K. Prifti S. Beckhove P. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection Proc Natl Acad Sci USA 91 1994 7430 7434
44. Lee C. Wu S. Ciernik I. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor Hum Gene Ther 8 1997 187 193
45. Livingston P. Wong G. Adluri S. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside J Clin Oncol 12 1994 1036 1044
46. Marchand M. Weynants P. Rankin E. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 Int J Cancer 63 1995 883 885
47. Mitchell M.S. Harel W. Kempf R.A. Active-specific immunotherapy for melanoma J Clin Oncol 8 1990 856 869
48. Morton D.L. Foshag L.J. Hoon D.S.B. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine Ann Surg 216 1992 463M82
49. Mukherji B. Chakraborty N. Yamasaki S. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells Proc Natl Acad USA 92 1995 8078 8082
50. Murphy G. Tjoa B. Ragde H. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen Prostate 29 1996 371 380
51. Musiani P. Modesti A. Giovarelli M. Cytokines, tumor-cell death and immunogenicity: A question of choice Immunol Today 18 1997 32 36
52. Nabel G. Gordon D. Bishop D. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes Proc Natl Acad Sci USA 93 1996 15388 15393
53. Nabel G.J. Nabel E.G. Yang Z.Y. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans Proc Natl Acad Sci U S A 90 1993 11307 11311
54. Naldini L. Blomer U. Gallay P. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272 1996 263 266
55. Noguchi Y. Richards E.C. Chen Y.T. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma Proc Natl Acad Sci U S A 92 1995 2219 2223
56. Oettgen H.F. Livingston P.O. Old L.J. Melanoma: Immunotherapy by active specific immunization Vincent J. DeVita T. Hellman S. Biologic Therapy of Cancer 1991 JB Lippincott Philadelphia 682 702
57. Papadopoulos E.B. Ladanyi M. Emanuel D. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation N Engl J Med 330 1994 1185 1191
58. Porgador A. Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes J Exp Med 182 1995 255 260
59. Prehn R.T. Main J.M. Immunity to methylcholanthrene-induced sarcomas J Natl Cancer Inst 18 1957 769 778
60. Putzer B.M. Hitt M. Mueller W.J. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenoviral vector act synergistically to facilitate tumor regression Proc Natl Acad Sci U S A 94 1997 10889 10894
61. Reeves M.E. Royalo R.E. Lam J.S. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene Cancer Res 56 1996 5672 5677
62. Ribas A. Butterfield L.H. McBride W.H. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells Cancer Res 57 1997 2865 2869
63. Schmidt W. Schweighoffer T. Herbst E. Cancer vaccines: The interleukin 2 dosage effect Proc Natl Acad Sci U S A 92 1995 4711 4714
64. Simons J.W. Jaffee E.M. Weben C.E. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 1537 1546
65. Slinghuff C. Vollmer R. Siegler H. Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients J Surg Oncol 39 1988 139 147
66. Tahara H. Zeh H.J. Storkus W.J. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo Cancer Res 54 1994 182 189
67. Tepper R.I. Mule J.J. Experimental and clinical studies of cytokine gene-modified tumor cells Hum Gene Ther 5 1994 153 164
68. Tepper R.I. Coffman R.L. Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4 Science 257 1992 548 551
69. Tepper R.I. Pattengale P.K. Leder P. Murine interleukin-4 displays potent antitumor activity in vivo Cell 57 1989 503 512
70. Townsend A. Bodmer H. Antigen recognition by class I-restricted T-lymphocytes Annu Rev Immunol 7 1989 601 624
71. Townsend S. Allison J. Tumor rejection after direct costimulation of CD8-I-T cells by B7-transfected melanoma cells Science 259 1993 368 370
72. Trinh Q. Austin E. Murray D. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase /ganciclovir enzyme/ prodrug systems in a human colorectal carcinoma cell line Cancer Res 55 1995 4808 4812
73. Tsang K. Zarema S. Nieroda C. Generation of human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine J Natl Cancer Inst 87 1995 982 990
74. Wan Y.H. Bramson J. Carter R. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination Hum Gene Ther 8 1997 1355 1363
75. Wang M. Bronte V. Chen P.W. Active immunotherapy of cancer with a non-replicating recombinant fowlpox virus encoding a model tumor-associated antigen J Immunol 154 1995 4685 4692
76. Zitvogel L. Tahara H. Robbins P. Cancer immunotherapy of established tumors with IL-12: Effective delivery by genetically engineered fibroblasts J Immunol 155 1995 1393 1403